Loading resource…

Romain Pirracchio, M.D., M.P.H., Ph.D., Djillali Annane, M.D., Ph.D.
The study pools individual patient data from various trials to assess the impact of intravenous hydrocortisone on 90-day all-cause mortality among patients with septic shock. It also examines secondary outcomes such as ICU and hospital discharge mortality, as well as the incidence of adverse events. The findings suggest that hydrocortisone may improve certain outcomes, but also carries risks of specific adverse effects.
No account needed